The new generation of anti-rejection drugs have the potential to improve graft survival

Mr Robert Johnson, Manchester Royal Infirmary

Trials have suggested that the drug could reduce the problem of organ rejection by as much as two-thirds.

The drug also appears to have fewer side effects than other immunosuppressants.

The only way to treat patients with end-stage kidney failure is with dialysis or transplantation.

Transplantation is a more effective treatment than dialysis, and therefore results in an improved quality of life for patients.

Rejection

Mr Robert Johnson said the drug could be a significant breakthrough

Patients who are given a new kidney have to take drugs for the rest of their lives to stop the body's immune system from rejecting the donor organ.

However, the drugs can damage the kidney themselves, and in many cases this ultimately leads to the failure of the donor organ.

When this happens the patient has to go back onto dialysis and join the waiting list for another transplant.

As there is a chronic shortage of donor organs, there is no guarantee that another organ will become available before the patient dies.

While 1,600 kidney transplants were carried out last year, 5,000 patients were still waiting for a donor organ.

Rapamune suppresses the immune system in a different way to existing treatments.

Transplant surgeon Mr Robert Johnson, of Manchester Royal Infirmary, said the new drug represented a "significant breakthrough".

He said: "The biggest problems we have at the moment are not having enough organs for transplantation and the long-term side effects of the drugs that we use in order to keep those grafts going.

"To have a drug that is hopefully equally powerful, but does not cause kidney damage would be a big advantage and hopefully would lead to longer life of the kidney."